Phase Ib / II Trial Evaluating the Association Myocet - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
- Indications Ovarian cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Gineco; MYCA
- 10 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.